Su, C., Chai, H., See, Y. and Kumar, R.S. 2024. GLYCEMIC CONTROL AND BODY WEIGHT EFFECTS OF SGLT2 INHIBITORS (EMPAGLIFLOZIN 25 MG, EMPAGLIFLOZIN 12.5 MG AND DAPAGLIFLOZIN 10 MG) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS: A SINGLE CENTRE STUDY. Journal of the ASEAN Federation of Endocrine Societies. 39, S1 (Jul. 2024), 25.